Lindsey Barrett
Role not yet determined Is this you? Add your title
Formerly Arkansas Affiliated with UAMS through 2022.
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Lindsey Barrett's research focuses on the pathogenesis of oncogenic viruses, particularly Kaposi's sarcoma-associated herpesvirus (KSHV). Her work investigates how KSHV interacts with host cells and other microbes, including SARS-CoV-2 and *Porphyromonas gingivalis*. Barrett has studied the role of KSHV in conditions such as Kaposi's sarcoma and lung cancer, exploring viral activation mechanisms and potential therapeutic targets. Her recent publications include studies on the lytic reactivation of KSHV induced by SARS-CoV-2 proteins and anti-COVID-19 drugs, as well as the coinfection of KSHV with *P. gingivalis* in HIV-positive individuals. Barrett has also explored novel therapeutic compounds for diffuse intrinsic pontine glioma and small-cell lung cancer. Her scholarship metrics include an h-index of 7 and 143 total citations across 9 publications. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Lu Dai and Steven R. Post.
Metrics
- h-index: 7
- Publications: 9
- Citations: 143
Selected Publications
-
Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target (2022)
-
Abstract LB072: SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus (2021)
-
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus (2021)
-
Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles (2021)
-
Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis (2020)
-
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus (2020)
-
Porphyromonas gingivalis coinfects with KSHV in oral cavities of HIV+ patients and induces viral lytic reactivation (2020)
-
Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG) (2020)
Collaboration Network
Top Collaborators
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG)
- Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Showing 5 of 8 shared publications
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG)
- Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Showing 5 of 8 shared publications
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG)
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Abstract LB072: SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Porphyromonas gingivalis coinfects with KSHV in oral cavities of HIV+ patients and induces viral lytic reactivation
- Abstract LB072: SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Porphyromonas gingivalis coinfects with KSHV in oral cavities of HIV+ patients and induces viral lytic reactivation
- Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis
- Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG)
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis
- Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis
- Kaposi's sarcoma‐associated herpesvirus and extracellular vesicles
- SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
- Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
Similar Researchers
Based on overlapping research topics